Skip to main content
Premium Trial:

Request an Annual Quote

Cancer's Clues

In a Business Report: The [San Francisco] Chronicle with Bloomberg post, John Lauerman says that "using faster, more accurate technologies, doctors are combing through ever-wider swaths of the human genome to pinpoint and counteract the causes of disease." According to the Dana-Farber Cancer Institute's Barrett Rollins, "cancer is among the most promising targets." Rollins tells Lauerman that genome screens are quickly becoming standard tests in the community, and adds, "if you're working at a cancer center and not thinking about this, you should be fired."

Bloomberg's Lauerman, a participant in the Personal Genome Project led by Harvard's George Church, says that while he "waited to see what my genome can reveal about my future health, I thought about whether I might face a heightened risk of cancer." Business Report adds that Lauerman's sequencing results will be detailed in future posts.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.